It’s not a lottery win. It’s not inheritance. There’s no secret.

So how does it actually work?

Compounding for glory

The maths is simpler than it sounds. In the early years, not much seems to happen. Year one, the £10k earns roughly £1,330 in interest. Underwhelming. But here’s the thing — that interest doesn’t disappear. It gets added to the pot. Next year, the interest earns interest. The year after that, the same. Each time the snowball rolls, it picks up a little more snow.

By year 10, the annual interest generated is around £9,000. By year 20, closer to £24,000 — more than the £6,000 in contributions going in that year. By year 30, the pot is generating over £120,000 in a single year. The contributions become almost irrelevant. The compounding has taken over.

Of the £1.33m final figure, only £190,000 represents actual money paid in — the £10k lump sum plus £500 a month for 30 years. The remaining £1.14m? Pure compounding. Time doing the heavy lifting. This is why I think it’s so important that if parents can, they should start an ISA or SIPP for a child at birth. They’ve got so much compounding ahead.

The SIPP wrapper makes it even more powerful. Unlike the ISA, basic-rate taxpayers get 20% tax relief on contributions, meaning that £500 a month only costs £400 out of pocket. Higher-rate taxpayers can claim back more still.

The catch, of course, is patience. As we can see compounding is brutally slow at the start and almost unbelievably fast at the end. The investors who benefit most are the ones who start early and contribute consistently.

What’s more, not everyone achieves 10% per annum. At 5%, for instance, the returns would be significantly lower.

Where to invest?

This is the most important question. The above is great in theory, but we need to find the stocks to do the job.

One name catching my eye as a possible pick for a long-term SIPP portfolio is Marvell Technology (NASDAQ:MRVL), a chipmaker that’s the essential plumbing for the AI revolution. The headline valuation isn’t great, which sounds alarming. But dig a little deeper and there’s an interesting case to make.

The forward price-earnings-to-growth (PEG) ratio sits at just 0.73, against a sector median of 1.4 — a massive discount and one of the few metrics where Marvell looks genuinely cheap relative to peers. But it’s the one that matters the most to me. That suggests the market may not be fully pricing in the company’s growth potential.

The risk? Marvell is heavily dependent on a small number of hyperscaler customers — Amazon, Microsoft, Google — for the bulk of its custom AI chip revenue. If any one of those relationships sours, or a hyperscaler decides to bring chip design fully in-house, the revenue hit could be severe.

Yet for patient SIPP investors with a 30-year horizon, I feel it’s well worth considering.

The post £10k in a SIPP today could be worth £1.33m in 30 years — with a bit of help appeared first on The Motley Fool UK.

And if it’s done in an ISA, all of the income will be free of tax. You’d need to earn approximately £55,000 per year from a salaried job to take home this much after tax.

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

This is the real beauty of the ISA. It allows returns to compound undisturbed by the taxman, accelerating long-term wealth creation and making high levels of passive income far more achievable.

Over time, the difference between tax-free and taxed returns can run into tens or even hundreds of thousands of pounds, especially for higher-rate taxpayers.

So, how much would an investor need in an ISA to earn this £40,000 per year?

Using a relatively cautious 4% income rate, an ISA would need to be worth around £1m.

At 5%, the required portfolio falls to roughly £800,000, while a 6% yield would bring it down to about £667,000.

However, it’s important to remember that higher yields are often less sustainable. A few years ago when the market was depressed, it was much easier to lock in big yields.

Today, some of those dividend stocks are trading much higher and the dividend yields (which are linked to to share prices, moving in the opposite direction) have fallen.

Building the portfolio takes time

With an annual ISA contribution limit of £20,000, it’s clear that you can’t build an £800,000 portfolio overnight. But when using half the allowance, an investor could theoretically get there in 25 years.

Knowing where to invest

As I said above, the theory is easy. Actually investing in the right stocks, trusts, funds, bonds etc, is the hard part.

At The Motley Fool, my peers and I believe the best way to build a portfolio for the long run is by choosing well-researched stocks.

And for me, that means starting with the raw data or running screens.

One stock that stands out from a valuation perspective is American chipmaker Marvell Technology (NASDAQ:MRVL).

Marvell stands out because its valuation looks far more attractive once growth is taken into account. While headline price-to-earnings (P/E) multiples appear elevated, the forward price-to-earnings-to-growth (PEG) ratio of 0.74 is less than half the sector median, suggesting the market is underpricing its earnings growth.

That matters far more than raw multiples for a company exposed to long-term data centre and AI demand. Crucially, this valuation is backed by a strong balance sheet, with modest net debt relative to a $72bn market capitalisation, giving Marvell flexibility to invest through the cycle.

Risks? Well it needs to execute to justify its higher P/E — 29 times. And the issue is that its ASIC — the specialised chips (not GPUs) used in servers and data centres — positioning is weaker than Broadcom.

Nonetheless, I definitely think it’s worth considering. Current forecasts suggest the forward P/E would drop to 11 times for 2029. That looks cheap for the sector.

The post How much do you need in an ISA for a £3,333 monthly second income? appeared first on The Motley Fool UK.

[Just beginning your investing journey? Check out our guide on how to start investing in the UK.]

Berkshire Hathaway

What it does: Berkshire Hathaway is a diversified conglomerate including insurance, utilities, and railroad operations.

By Stephen Wright. Despite the US stock market looking slightly expensive at the moment, one stock stands out to me as a buying opportunity. It’s Berkshire Hathaway (NYSE:BRK.B). 

When I’m looking for shares to buy, the most important thing is a business that has a long-term competitive advantage. And Warren Buffett’s company fits the bill. 

Berkshire’s subsidiaries operate in a number of regulated industries, including insurance, utilities, and railroads. And as Buffett pointed out, this brings risk as regulators aren’t always predictable.

Nonetheless, all three are businesses where demand is highly predictable, even if regulation isn’t. And the barriers to entry for competitors are extremely high.

Trading at a price-to-book (P/B) ratio of 1.57 while earning a return on equity in excess of 18%, I think the stock is good value. That’s why its my largest stock investment and one I plan to continue buying.

Stephen Wright owns shares in Berkshire Hathaway.

Boston Scientific

What it does: Boston Scientific is a global medical device manufacturer. Their products tackle a wide range of medical conditions from heart disease to urology.  

By Harshil Patel : I reckon one of the best US stocks in the healthcare field is Boston Scientific (NYSE:BSX). This medical device manufacturer is going from strength to strength. It recently reported a strong first quarter with sales exceeding expectations.

Sales jumped by 15% versus the first quarter of 2023, driven by an innovative portfolio of products. It launched nearly 90 new products last year.

For companies to grow sales, innovation is one of the most important factors to consider. And Boston Scientific invests in research and development to create innovative new products and solutions.

One standout sector that I’d mention is Electrophysiology, which grew its sales by a whopping 72%. The jump was driven by encouraging adoption of its Farapulse platform.

Bear in mind that this industry is highly regulated. And Boston Scientific faces risks from both regulatory compliance and lawsuits.

That said, in the long term, an ageing population and other lifestyle factors are likely to support its growth.

Harshil Patel does not own shares in Boston Scientific.

DraftKings

What it does: DraftKings runs daily fantasy sports competitions and provides online sports betting services.

By Charlie Carman. DraftKings (NASDAQ:DKNG) is a relatively young company operating in a new market — online sports betting in the USA.

Since the Supreme Court lifted a federal ban in 2018, individual states have rushed to legalise the practice. DraftKings now has a presence in 27 of those markets.

With votes on sports betting due over the coming years in populous states like California, Florida, and Texas, there’s significant potential for further expansion.

Crucially, DraftKings is performing well across key growth metrics. Monthly unique players soared to 3.5m in Q4, representing a 37% year-on-year increase, and 2024’s revenue guidance has been lifted to a midpoint of $4.78bn.

Granted, DraftKings is still unprofitable, and competitive pressure from Flutter Entertainment and Entain poses risks for the firm’s market share.

Nonetheless, I think this market will be big enough to accommodate several major players and DraftKings looks well-positioned to benefit from further growth in the industry.

Charlie Carman owns shares in DraftKings. 

Marvell Technology

What it does: Delaware-based chip manufacturer that designs and produces semiconductors and related technology.

By Mark David Hartley. Despite a $55bn market cap and $64 share price, Marvell (NASDAQ:MRVL) is a small player in the booming semiconductor market. Unlike AMD and Nvidia, it doesn’t publicly retail under its own brand but supplies components to other tech firms in the artificial intelligence (AI) field. I’ve been invested for a while with little to report but now it looks ready to take off. Earlier this month, Bank of America reiterated its buy rating on the stock with a price target of $95. Other analysts on average eye an $88 target. 

Unfortunately, Marvell’s profits are very much tied to the success of the wider tech industry, so any falter there could hit it hard. AI is still a nascent industry running on a lot of speculation, so it falls in the ‘high risk/high reward’ area of investing. I like Marvell’s prospects but I’d balance it out with other stable stocks.

Mark David Hartley owns shares in Marvell Technology, Nvidia, and AMD.

Palo Alto 

What it does: Palo Alto Networks markets itself as the world’s cybersecurity leader, via the provision of security tools.

By Jon Smith. When looking across the pond, I’m a big fan of Palo Alto Networks (NASDAQ:PANW). I bought the stock last month after the share price dipped following worse than expected results in February.

Even with the tumble following results, the stock is still up 61% over the past year. This speaks to the increase in demand for cybersecurity. I also bought this as a way to get exposure to artificial intelligence (AI). The rise in AI means that more complex cyber scams are occurring. Therefore, companies like Palo Alto that are developing products for this should benefit from higher demand.

A risk is the high benchmark of expectations that investors have. For example, the quarterly results in February were good (revenue jumped 19% year-on-year) but just not as good as the lofty expectations. Even with this, I think the scope for significant growth in coming years is there.

Jon Smith owns shares of Palo Alto.

The post Best US stocks to consider buying in May appeared first on The Motley Fool UK.